Literature DB >> 17606477

Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells.

Christopher F MacManus1, Johanna Pettigrew, Angela Seaton, Catherine Wilson, Pamela J Maxwell, Silvia Berlingeri, Colin Purcell, Maryalice McGurk, Patrick G Johnston, David J J Waugh.   

Abstract

We have shown previously that interleukin-8 (IL-8) and IL-8 receptor expression is elevated in tumor cells of human prostate biopsy tissue and correlates with increased cyclin D1 expression. Using PC3 and DU145 cell lines, we sought to determine whether IL-8 signaling regulated cyclin D1 expression in androgen-independent prostate cancer (AIPC) cells and to characterize the signaling pathways underpinning this response and that of IL-8-promoted proliferation. Administration of recombinant human IL-8 induced a rapid, time-dependent increase in cyclin D1 expression in AIPC cells, a response attenuated by the translation inhibitor cycloheximide but not by the RNA synthesis inhibitor, actinomycin D. Suppression of endogenous IL-8 signaling using neutralizing antibodies to IL-8 or its receptors also attenuated basal cyclin D1 expression in AIPC cells. Immunoblotting using phospho-specific antibodies confirmed that recombinant human IL-8 induced rapid time-dependent phosphorylation of Akt and the mammalian target of rapamycin substrate proteins, 4E-BP1 and ribosomal S6 kinase, resulting in a downstream phosphorylation of the ribosomal S6 protein (rS6). LY294002 and rapamycin each abrogated the IL-8-promoted phosphorylation of rS6 and attenuated the rate of AIPC cell proliferation. Our results indicate that IL-8 signaling (a) regulates cyclin D1 expression at the level of translation, (b) regulates the activation of proteins associated with the translation of capped and 5'-oligopyrimidine tract transcripts, and (c) activates signal transduction pathways underpinning AIPC cell proliferation. This study provides a molecular basis to support the correlation of IL-8 expression with that of cyclin D1 in human prostate cancer and suggests a mechanism by which this chemokine promotes cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606477     DOI: 10.1158/1541-7786.MCR-07-0032

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  53 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.

Authors:  Sathish Kasina; Jill A Macoska
Journal:  Mol Cell Endocrinol       Date:  2012-01-08       Impact factor: 4.102

3.  Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment.

Authors:  Jong-Hyuk Kim; Aric M Frantz; Katie L Anderson; Ashley J Graef; Milcah C Scott; Sally Robinson; Leslie C Sharkey; Timothy D O Brien; Erin B Dickerson; Jaime F Modiano
Journal:  Exp Cell Res       Date:  2014-02-25       Impact factor: 3.905

4.  IL-8 is upregulated in cervical cancer tissues and is associated with the proliferation and migration of HeLa cervical cancer cells.

Authors:  Linlin Jia; Fengying Li; Mingliang Shao; Wei Zhang; Chunbin Zhang; Xiaolian Zhao; Haiyan Luan; Yaling Qi; Pengxia Zhang; Lichun Liang; Xiuyue Jia; Kun Zhang; Yan Lu; Zhe Yang; Xiulin Zhu; Qi Zhang; Jiwei Du; Weiqun Wang
Journal:  Oncol Lett       Date:  2017-11-10       Impact factor: 2.967

5.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

6.  A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1.

Authors:  Olga C Rodriguez; Edwin W Lai; Sarada Vissapragada; Caroline Cromelin; Maral Avetian; Patricia Salinas; Hida Ramos; Bhaskar Kallakury; Mathew Casimiro; Michael P Lisanti; Herbert B Tanowitz; Karel Pacak; Robert I Glazer; Maria Avantaggiati; Chris Albanese
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

7.  Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy.

Authors:  Jiajia Ma; Zijia Ren; Yang Ma; Lu Xu; Ying Zhao; Chaogu Zheng; Yinghui Fang; Ting Xue; Baolin Sun; Weihua Xiao
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

Review 8.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.

Authors:  Todd M Morgan; Theodore D Koreckij; Eva Corey
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

9.  Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.

Authors:  Rajendra K Singh; Bal L Lokeshwar
Journal:  Mol Cancer       Date:  2009-07-31       Impact factor: 27.401

10.  Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

Authors:  A Seaton; P J Maxwell; A Hill; R Gallagher; J Pettigrew; R H Wilson; D J J Waugh
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.